Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane

Acta Anaesthesiologica Scandinavica

Volumn 44, Issue 3, 2000, Pages 334-337

  Snoeck, M M J ^a   Gielen, M J M ^b   Tangerman, A ^b   Van Egmond, J ^b   Dirksen, R ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b NONE

Author keywords

Gas chromatography; In vitro contracture test; Malignant hyperthermia; Sevoflurane

Indexed keywords

HALOTHANE; SEVOFLURANE;

ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG POTENCY; DRUG SOLUBILITY; GAS CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; PRIORITY JOURNAL;

ANESTHETICS, INHALATION; CAFFEINE; HUMANS; MALIGNANT HYPERTHERMIA; METHYL ETHERS; MUSCLE CONTRACTION; MUSCLE, SKELETAL;

EID: 0034108199     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-6576.2000.440320.x     Document Type: Article

References (17)

1. Ranklev E, Henriksson K, Fletcher R, Germundsson K, Oldfors A, Kalimo H. Clinical and muscle biopsy findings in malignant hyperthermia susceptibility. Acta Neurol Scand 1986: 74: 452-459.
2. Fu E, Scharf J, Mangar D, Miller W. Malignant hyperthermia involving the administration of desflurane. Can J Anaesth 1996: 43: 687-690.
3. Shulman M, Braverman B, Ivankovich A, Gronert G. Sevoflurane triggers malignant hyperthermia in swine. Anesthesiology 1981: 54: 259-260.
4. Otsuka H, Komura Y, Mayumi T, Yamamura T, Kemmotsu O, Mukaida K. Malignant hyperthermia during sevoflurane anesthesia in a child with central core disease. Anesthesiology 1991: 75: 699-710.
5. Ochiai R, Toyoda Y, Nishio I, Takeda J, Sekiguchi H, Fukushima K et al. Possible association of malignant hyperthermia with sevoflurane anesthesia. Anesth Analg 1992: 74: 616-618.
6. Maeda H, Iranami H, Hatano Y. Delayed recovery from muscle weakness due to malignant hyperthermia during sevoflurane anesthesia. Anesthesiology 1997: 87: 425-426.
7. Ducart A, Adnet P, Renaud B, Riou B, Krivosic-Horber R. Malignant hyperthermia during sevoflurane administration. Anesth Analg 1995: 80: 609-611.
8. Claußen D, Wuttig K, Freudenberg J, Claußen A. Maligne Hyperthermie und sevofluran - eine Kasuistik. Anästhesiol Intensivmed Notfallmed Schmerzther 1997: 32: 641-644.
9. European MH Group. A protocol for the investigation of malignant hyperthermia (MH) susceptibility. Br J Anaesth 1984: 56: 1267-1269.
10. Hopkins P, Halsall P, Ellis F. Diagnosing malignant hyperthermia susceptibility. Anaesthesia 1994: 49: 373-375.
11. Ørding H. for the European Malignant Hyperthermia Group. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997: 41: 955-966.
12. Zbinden AM, Frei FJ, Funk B, Thomson DA, Westenskow D. Determination of the partial pressure of halothane (or isoflurane) in blood. Br J Anaesth 1985: 57: 796-802.
13. Larach M, Localio A, Allen G, Denborough M, Ellis F, Gronert G et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994: 80: 771-779.
14. Urwyler A, Funk B, Censier K, Drewe J. Effect of halothane equilibration kinetics on in vitro muscle contractures for malignant hyperthermia screening. Acta Anaesthesiol Scand 1992: 36: 115-118.
15. Ørding H. The European MH Group: protocol for in vitro diagnosis of susceptibility to MH and preliminary results. In: Britt BA, ed. Malignant hyperthermia. Boston: Martinus Nijhoff, 1987: 269-277.
16. Halsall P, Caine P, Ellis F. Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognised. Br J Anaesth 1979: 51: 949-954.
17. Bendixen D, Skovgaard L, Ørding H. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Acta Anaesthesiol Scand 1997: 41: 480-484.